Will Europe block the Pandemic Agreement because of one word?

This commentary originally appeared in the Brussels Times, and is available here. The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...
INB co-chairs, Precious Matsoso from South Africa and Roland Driece from the Netherlands opening the session on 18 June

Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert...

Negotiators of a Pandemic Treaty should heed the recommendations, published 15 July in the BMJ Global Health, to design a fair global system for...

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

Legal tools that lower medicines prices have expanded access to medicines for over two...

LONDON, UK: Millions of people are priced out of access to life-saving medicines. Use of legal tools to reduce prices has been under-reported and...

The € 7.4 billion for Covid-19 product and vaccine development needs a few strings...

On 4 May 2020, European Commission President Ursula von der Leyen hosted the Coronavirus Global Response conference, an on-line pledging event to accelerate the...

Dutch Minister of Health writes open letter to pharma, threatens to name and shame

"Dear Pharma," writes the Dutch Minister of Health, Bruno Bruins in an open letter in the daily newspaper the Volkskrant, "Last week two messages jumped...

“This week, the medicines were not there”: What is at stake in the pandemic...

Earlier this week I listened to a testimony from a community worker at a maternity ward where HIV-positive women gave birth. 17 babies were...

The Waiver that Wasn’t: Is the pharma lobby responsible?

Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...

TRIPS, technology transfer and access to pandemic countermeasures: What the WHO  Pandemic Treaty must...

The scrambling for access to Covid-19 vaccines by developing countries has reignited the debate on the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS)...

Why The Request By Least Developed Countries For An Extension Of The Transitional Period...

On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...